Here are the DEF 14A proxy statements from Ligand Pharms General CVR (LGNYZ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LGNYZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LGNYZ filings page.
Ligand Pharmaceuticals Incorporated is asking stockholders to vote at a virtual annual meeting on June 5, 2026. Stockholders will elect eight directors, ratify Ernst & Young LLP as auditor for 2026, approve an advisory say‑on‑pay vote, and consider an amendment and restatement of the 2002 Stock Incentive Plan.
The proxy highlights a royalty‑focused biopharmaceutical model that generated strong 2025 results, including 48% royalty revenue growth and a 42% increase in full‑year adjusted EPS over the prior year. Management attributes this to a lean cost structure, diversified royalty portfolio, and successful partner product launches.
The amended equity plan would add 600,000 shares to the share reserve, eliminate the fungible pool formula, raise the limit on incentive stock options, update director compensation caps, and extend the plan term by ten years. Ligand also emphasizes sustainability initiatives, including a $2.6 million solar investment, and outlines governance practices such as independent committees, a clawback policy, stock ownership guidelines and annual say‑on‑pay votes.